Evidence map›Paper›PMID 40943171›Full record

ReviewInternational journal of molecular sciences2025

Exosomal Non-Coding RNAs as Potential Biomarkers for Alzheimer's Disease: Advances and Perspectives in Translational Research.

Simoneide Souza Titze-de-Almeida, Clara Luna Marina, Milena Vieira Ramos, Letícia Dias Dos Santos Silva, Pedro Renato de Paula Brandão, Diógenes Diego de Carvalho Bispo, Felipe Von Glehn, Ricardo Titze-de-Almeida

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Extracellular RNAs as Messengers and Early Biomarkers in Neurodegeneration.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simoneide Souza Titze-de-AlmeidaResearch Center for Major Themes-Neurodegenerative Disorders Division, University of Brasília, Brasília 70910-900, Federal District, Brazil.ORCID 0000-0001-6122-054X
Clara Luna MarinaResearch Center for Major Themes-Neurodegenerative Disorders Division, University of Brasília, Brasília 70910-900, Federal District, Brazil.ORCID 0000-0002-0819-0756
Milena Vieira RamosFaculdade de Medicina, University of Rio Verde, Aparecida de Goiânia 74923-590, Goiás, Brazil.ORCID 0000-0003-3553-5649
Letícia Dias Dos Santos SilvaResearch Center for Major Themes-Neurodegenerative Disorders Division, University of Brasília, Brasília 70910-900, Federal District, Brazil.
Pedro Renato de Paula BrandãoSírio-Libanês Hospital, Brasilia 70200-730, Federal District, Brazil.ORCID 0000-0002-1191-2078
Diógenes Diego de Carvalho BispoBrasília University Hospital, University of Brasília, Brasília 70910-900, Federal District, Brazil.ORCID 0000-0001-6660-2766
Felipe Von GlehnBrasília University Hospital, University of Brasília, Brasília 70910-900, Federal District, Brazil.ORCID 0000-0002-1004-7641
Ricardo Titze-de-AlmeidaResearch Center for Major Themes-Neurodegenerative Disorders Division, University of Brasília, Brasília 70910-900, Federal District, Brazil.ORCID 0000-0002-5019-4742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by memory loss and cognitive decline, which significantly impacts patients' quality of life and imposes substantial emotional, practical, and economic burdens on their families. As the most common cause of senile dementia, AD currently affects approximately 50 million people worldwide, with projections indicating a threefold increase by 2050 due to rising life expectancy and an aging global population. Diagnosis of AD remains challenging. Neuroimaging techniques reveal atrophy in critical brain regions, particularly in the cortex, hippocampus, and limbic system, which are essential substrates for memory, personality changes, and other cognitive functions. The hallmark molecular changes associated with AD include the accumulation of β-amyloid plaques and the formation of tau protein tangles. Several underlying mechanisms contribute to neuron loss, such as oxidative stress, neuroinflammation, microbial dysbiosis, and insulin resistance. In this context, exosomes-small extracellular vesicles that facilitate cell communication-transport proteins, DNA, mRNA, and non-coding RNA (ncRNA), all of which play a significant role in the neurobiology of AD. Furthermore, emerging research indicates that exosomal ncRNAs may serve as promising biomarkers for AD, offering the possibility of improved diagnostic precision. This review explores the potential of exosomal ncRNAs-specifically circular RNAs and microRNAS-as non-invasive biomarkers for AD, highlighting recent advances and future directions in translational studies.

Indexed as

Alzheimer DiseaseExosomesRNA, UntranslatedAnimalsBiomarkersHumansMicroRNAsRNA, CircularTranslational Research, BiomedicalBiomarkersMicroRNAsRNA, CircularRNA, UntranslatedAlzheimer’s diseasebiomarkerscircRNAsmiRNAstau proteinβ-amyloid

Identifiers

PMID40943171
PMCPMC12427810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.